Literature DB >> 11193728

Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement.

N Sengül1, S Demirer, M A Yerdel, G Terzioğlu, B Akin, A Gürler, A Tüzüner.   

Abstract

Behçet disease (BD) is an inflammatory illness that may attack several systems. Vascular involvement with thrombosis is one of the basic characteristics of this disease. The etiology of thrombosis tendency in BD has not been understood well. In this study, the role of primary coagulation parameters in patients with BD who have thromboembolic events was evaluated. In addition, the relation between the clinical activity of the disease and these parameters was compared. A total of 96 patients with a diagnosis of BD were studied at Ankara University, Medical School, Department of General Surgery and Behçet Center. BD patients were separated into two groups with respect to vascular involvement. Group A contained 22 patients with vascular attacks, and group B contained 74 patients without vascular attacks. In addition, 25 healthy persons comprised the control group (group C). The coagulation parameters assessed included protein C, protein S, antithrombin III activity, fibrinogen level, prothrombin time (PT), and partial thromboplastin time (PTT). There were no differences among the three groups with respect to protein C, protein S, fibrinogen, PT, and PTT values (p > 0.05). The antithrombin III value was found to be high in BD patients compared to those in the control group (p = 0.011). There was no difference regarding the antithrombin III value between BD patients with or without vascular attacks (p = 0.954). There was no correlation between the activity of disease and coagulation parameters (p > 0.05), but a positive correlation was seen between the duration of illness and vascular involvement. Fifty percent of patients who had had BD more than 8 years had vascular involvement (p = 0.002). We could not determine a specific pathology in relation to coagulation parameters that could explain the etiology of thrombosis in patients with BD. The elevated antithrombin III levels in patients with BD (compared to controls) may be due to a compensatory defense mechanism against increased procoagulant activity. There was a correlation between the duration of illness and vascular involvement.

Entities:  

Mesh:

Year:  2000        PMID: 11193728     DOI: 10.1007/s002680010282

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  7 in total

Review 1.  Behçet's disease and thrombophilia.

Authors:  M Leiba; Y Sidi; H Gur; A Leiba; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Decreased protein S activity is related to the disease activity of Behcet's disease.

Authors:  Seong Ryul Kwon; Mie Jin Lim; Shin Goo Park; Yeon Sook Moon; Won Park
Journal:  Rheumatol Int       Date:  2006-09-13       Impact factor: 2.631

3.  Haemostatic Parameters in Patients with Behçet's Disease.

Authors:  Juma K Alkaabi; David Gravell; Hamood Al-Haddabi; Anil Pathare
Journal:  Sultan Qaboos Univ Med J       Date:  2014-04-07

4.  Internal jugular vein thrombosis in Behcet's disease: a rare complication.

Authors:  Muhammet Bilici; Yavuz Pehlivan; Gezmis Kimyon; Bunyamin Kisacik
Journal:  BMJ Case Rep       Date:  2014-09-19

5.  Behçet's Syndrome and Thrombosis.

Authors:  Emire Seyahi; Sebahattin Yurdakul
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

6.  Behcet's disease and cardiovascular involvement: our experience of asymptomatic Behcet's patients.

Authors:  Zeynep Ulusan; Ayse Serap Karadag; Mehmet Tasar; Mehmet Kalender; Osman Tansel Darcin
Journal:  Cardiovasc J Afr       Date:  2014 Mar-Apr       Impact factor: 1.167

7.  Behçet's disease complicated with thrombosis: a report of 93 Chinese cases.

Authors:  Xiuhua Wu; Guohua Li; Xinxiang Huang; Li Wang; Wanli Liu; Yan Zhao; Wenjie Zheng
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.